Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes. | Aplastic Anemia and MDS International Foundation

Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes.

Journal Title: 
Am J Hematol
Author(s): 
Gangat N, Patnaik MM, Begna K, Kourelis T, Knudson RA, Ketterling RP, Hodnefield JM, Hanson CA, Pardanani A, Tefferi A.
Primary Author: 
Gangat N
Original Publication Date: 
Monday, May 20, 2013

Cytogenetic classification by the revised international prognostic scoring system (IPSS-R) and the prognostic value of monosomal karyotype (MK) were assessed in 783 patients with primary myelodysplastic syndromes (MDS). At 22 months median follow-up, 562 (72%) deaths were recorded. Percentages of patients with IPSS-R "very good", "good", "intermediate", "poor" and "very poor" cytogenetic categories was 5%, 63%, 18%, 4% and 10%, respectively. The corresponding median survivals were 21, 40, 24, 18 and 6.5 months and the inter-group differences (good vs. very good/intermediate/poor vs. very poor; p<0.01) or similarities (very good vs. intermediate vs. poor; p=0.79) were not significantly modified in multivariable analysis. Results were similar when analysis was restricted to 602 patients managed by supportive care. MK adversely affected survival in both poor and very poor karyotype groups (p<0.01). In conclusion, we were unable to confirm the prognostic superiority of IPSS-R-very good karyotype or prognostically distinguish between very good, intermediate and poor karyotypes. Furthermore, we show additional prognostic information from MK in poor/very poor karyotype.

Bone Marrow Diseases: